PCN25 COST-EFFECTIVENESS OF NIVOLUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA REGARDLESS OF BRAF MUTATION STATUS FROM A BRAZILIAN PUBLIC HEALTHCARE SYSTEM

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.08.093 ◽

2019 ◽

Vol 19 ◽

pp. S17-S18

Author(s):

J.P.D.S.N. Lima ◽

P. Marinheiro ◽

G. Bernardino

Keyword(s):

Cost Effectiveness ◽

Healthcare System ◽

Braf Mutation ◽

Advanced Melanoma ◽

Public Healthcare ◽

Line Treatment ◽

First Line ◽

Mutation Status ◽

Public Healthcare System ◽

First Line Treatment

Download Full-text

PCN24 COST-EFFECTIVENESS OF NIVOLUMAB COMBINED WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA FOR PATIENTS WITH BRAF+ MUTATION FROM A BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

Value in Health Regional Issues ◽

10.1016/j.vhri.2019.08.092 ◽

2019 ◽

Vol 19 ◽

pp. S17

Author(s):

J.P.D.S.N. Lima ◽

P. Marinheiro ◽

G. Bernardino

Keyword(s):

Cost Effectiveness ◽

Healthcare System ◽

Braf Mutation ◽

Advanced Melanoma ◽

Public Healthcare ◽

Line Treatment ◽

First Line ◽

System Perspective ◽

Healthcare System Perspective ◽

First Line Treatment

Download Full-text

PCN102 COST-EFFECTIVENESS OF NIVOLUMAB VERSUS DACARBAZINE IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA FROM BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

Value in Health ◽

10.1016/j.jval.2020.04.1597 ◽

2020 ◽

Vol 23 ◽

pp. S41

Author(s):

A.P. Casagrande Oliveira ◽

S. Hamza ◽

A. Koloszuk ◽

P. Marinheiro ◽

G. Bernardino

Keyword(s):

Cost Effectiveness ◽

Healthcare System ◽

Advanced Melanoma ◽

Public Healthcare ◽

Line Treatment ◽

First Line ◽

System Perspective ◽

Healthcare System Perspective ◽

Public Healthcare System ◽

First Line Treatment

Download Full-text

Cost-effectiveness of new therapies in first-line treatment of advanced melanoma for patients with independent BRAF mutation status from a Brazilian private payer perspective.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.e21546 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. e21546-e21546

Author(s):

Christina Matteucci ◽

Joao PsDN Lima ◽

Graziela Bernardino ◽

Ana Paula Oliveira ◽

Daniela Galdeano Maia

Keyword(s):

Cost Effectiveness ◽

Braf Mutation ◽

Advanced Melanoma ◽

Line Treatment ◽

First Line ◽

Mutation Status ◽

New Therapies ◽

Payer Perspective ◽

First Line Treatment ◽

Private Payer

Download Full-text

PND32 - COST COMPARISON OF MULTIPLE SCLEROSIS FIRST LINE TREATMENT WITH AVAILABLE INTERFERONS WITHIN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM

Value in Health ◽

10.1016/j.jval.2018.09.1999 ◽

2018 ◽

Vol 21 ◽

pp. S334

Author(s):

J Rigolon ◽

LF Conceição

Keyword(s):

Multiple Sclerosis ◽

Healthcare System ◽

Cost Comparison ◽

Public Healthcare ◽

Line Treatment ◽

First Line ◽

Public Healthcare System ◽

First Line Treatment

Download Full-text

ELTROMBOPAG AS FIRST-LINE TREATMENT IN SEVERE APLASTIC ANEMIA: A COST-EFFECTIVENESS ANALYSIS FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

Hematology Transfusion and Cell Therapy ◽

10.1016/j.htct.2021.10.063 ◽

2021 ◽

Vol 43 ◽

pp. S37

Author(s):

MA Salvino ◽

C Bonfim ◽

RT Calado ◽

H Kim ◽

JF Bertinato ◽

...

Keyword(s):

Cost Effectiveness ◽

Aplastic Anemia ◽

Healthcare System ◽

Public Healthcare ◽

Line Treatment ◽

First Line ◽

System Perspective ◽

Healthcare System Perspective ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-Effectiveness of Nivolumab in Combination with Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden: Analysis Using 28-Month Overall Survival from Checkmate 067

Value in Health ◽

10.1016/j.jval.2017.08.261 ◽

2017 ◽

Vol 20 (9) ◽

pp. A444

Author(s):

T Baker ◽

VF Paly ◽

J Sabater ◽

C Holmberg ◽

M Hultberg ◽

...

Keyword(s):

Overall Survival ◽

Cost Effectiveness ◽

Advanced Melanoma ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text

Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

Cost Effectiveness and Resource Allocation ◽

10.1186/s12962-020-0200-9 ◽

2020 ◽

Vol 18 (1) ◽

Cited By ~ 1

Author(s):

Herbert H. Loong ◽

Carlos K. H. Wong ◽

Linda K. S. Leung ◽

S. C. Tan ◽

Jason Jen ◽

...

Keyword(s):

Hong Kong ◽

Cost Effectiveness ◽

Standard Of Care ◽

Cost Effectiveness Analysis ◽

Advanced Melanoma ◽

Line Treatment ◽

First Line ◽

Effectiveness Analysis ◽

First Line Treatment

Download Full-text

Cost-effectiveness of various maintenance therapies based on mutation status following first-line treatment of primary epithelial ovarian cancer in the United States

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.07.050 ◽

2020 ◽

Vol 159 (2) ◽

pp. e14

Author(s):

Courtney Alexis Penn ◽

Melissa Spring Wong ◽

Christine Walsh

Keyword(s):

United States ◽

Ovarian Cancer ◽

Cost Effectiveness ◽

Epithelial Ovarian Cancer ◽

The United States ◽

Line Treatment ◽

First Line ◽

Mutation Status ◽

Primary Epithelial Ovarian Cancer ◽

First Line Treatment

Download Full-text

Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.3506 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 3506-3506 ◽

Cited By ~ 33

Author(s):

C. Bokemeyer ◽

C. Kohne ◽

P. Rougier ◽

C. Stroh ◽

M. Schlichting ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Braf Mutation ◽

Line Treatment ◽

First Line ◽

Mutation Status ◽

First Line Treatment

Download Full-text

Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced Melanoma

Value in Health ◽

10.1016/j.jval.2016.09.2198 ◽

2016 ◽

Vol 19 (7) ◽

pp. A730

Author(s):

TM Baker ◽

VF Paly ◽

J Sabater ◽

T Okoro ◽

S Kotapati ◽

...

Keyword(s):

Cost Effectiveness ◽

Advanced Melanoma ◽

Line Treatment ◽

First Line ◽

First Line Treatment

Download Full-text